Spyre Therapeutics (SYRE) Non Operating Investment Income (2023)
Spyre Therapeutics (SYRE) reported Non Operating Investment Income of $30000.0 for Q4 2023, up 100.12% quarter-over-quarter from -$25.4 million in Q3 2023.
Spyre Therapeutics (SYRE) Non Operating Investment Income (2023) Analysis & Trends
Spyre Therapeutics has reported Non Operating Investment Income for 1 years, with the latest figure at $30000.0 in Q4 2023.
- For the quarter ending Q4 2023, Non Operating Investment Income changed N/A year-over-year to $30000.0; the trailing twelve-month figure through Dec 2024 stood at $30000.0 (up 100.04% YoY), and the FY2023 full-year result was -$83.5 million, changed N/A from the prior year.
- Non Operating Investment Income for Q4 2023 stood at $30000.0, up from -$25.4 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $30000.0 in Q4 2023, with the low at -$58.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Sep 30, 2023 | -25.40 Mn |
| Sep 30, 2023 | -25.40 Mn |
| Jun 30, 2023 | -58.20 Mn |
| Jun 30, 2023 | -58.20 Mn |